会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • FLOW-THROUGH CONCRETE EDGE FORMING SYSTEM AND METHOD
    • 流动通过混合边缘成形系统和方法
    • WO2007145891A3
    • 2008-12-18
    • PCT/US2007013147
    • 2007-06-04
    • SULLIVAN JAMES C
    • SULLIVAN JAMES C
    • E04B1/16E01C7/00E01C9/00E01C11/22E01C15/00E04B2/00E04D1/36
    • E04G15/061E04G13/06
    • A flow-through concrete edge forming system (10) utilizes a body member (12) that has perforations (20) thereon. The body member (12) is placed at an elevation transition area of a monolithic slab (S) as an edge forming form. Once the slab (S) is poured, a parge coating (P) is placed on the outer surface of the body member (12) such that the parge coating (P) either binds to the outer surface or penetrates the body member (12) through a series of perforations on the body member (12) in order for the parge coating (P) to bind with the concrete of the slab (S) which has yet to set thereby producing a clean and solid finish of the outer surface of the slab (S) at the transition area. The body member ( 12) may have either a rectangular profile (1 12), a keyhole profile (214) or may have the perforations (20) on a series of inwardly directed deformations (18).
    • 流通式混凝土边缘形成系统(10)利用其上具有穿孔(20)的主体构件(12)。 主体构件(12)作为边缘形成形式放置在单片板(S)的仰角过渡区域。 一旦浇注了板坯(S),则在本体件(12)的外表面上放置一个涂层(P),使得该涂层涂层(P)或者结合外表面或者穿透本体件(12) 通过在本体构件(12)上的一系列穿孔,以便使涂层(P)与尚未固化的板坯(S)的混凝土结合,从而产生清洁和坚固的外表面 板坯(S)在过渡区域。 主体构件(12)可以具有矩形轮廓(112),锁眼轮廓(214)或者可以在一系列向内指向的变形(18)上具有穿孔(20)。
    • 3. 发明申请
    • METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS
    • 用于放大丙型肝炎病毒核酸的方法
    • WO2010090857A3
    • 2010-11-25
    • PCT/US2010021589
    • 2010-01-21
    • VERTEX PHARMAKWONG ANN DFRANTZ JAMES DANIELBARTELS DOUGLAS JLIN CHAOSHAMES BENJAMINSEEPERSAUD SHEILALIPPKE JUDITH AKIEFFER TARA LZHOU YIZHANG EILEEN ZSULLIVAN JAMES C
    • KWONG ANN DFRANTZ JAMES DANIELBARTELS DOUGLAS JLIN CHAOSHAMES BENJAMINSEEPERSAUD SHEILALIPPKE JUDITH AKIEFFER TARA LZHOU YIZHANG EILEEN ZSULLIVAN JAMES C
    • C12Q1/68
    • C12Q1/707C12Q1/6883
    • A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO: 12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.
    • 在HCV感染样品中扩增HCV核酸的方法包括通过两阶段PCR从样品中扩增与HCV RNA基因组互补的DNA模板的片段,其中第一阶段PCR使用第一外部引物 和第二外引物,第二阶段PCR采用第一内引物和第二内引物。 第一外引物的核苷酸序列包含SEQ ID NO:2所示的核苷酸序列; 或SEQ ID NO:9,其中任选地1,2或3个核苷酸是比SEQ ID NO:9的核苷酸更多的核苷酸。第二外部引物的核苷酸序列包含SEQ ID NO:3或4所示的核苷酸序列; 或如SEQ ID NO:10或11所示的核苷酸序列,其中任选1,2或3个核苷酸是与SEQ ID NO:10和11相同的其它核苷酸。第一内引物的核苷酸序列包含核苷酸序列 如SEQ ID NO:5所示; 或SEQ ID NO:12,其中任选地1,2或3个核苷酸是与SEQ ID NO:12相同的其它核苷酸。第二内引物的核苷酸序列包含SEQ ID NO:6或7所示的核苷酸序列 ; 或如SEQ ID NO:13或14所示的核苷酸序列,其中任选地1,2或3个核苷酸是与SEQ ID NO:13和14相同的其它核苷酸。
    • 4. 发明申请
    • METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS
    • 扩增丙型肝炎病毒核酸的方法
    • WO2010090857A2
    • 2010-08-12
    • PCT/US2010/021589
    • 2010-01-21
    • VERTEX PHARMACEUTICALS INCORPORATEDKWONG, Ann, D.FRANTZ, James, DanielBARTELS, Douglas, J.LIN, ChaoSHAMES, BenjaminSEEPERSAUD, SheilaLIPPKE, Judith, A.KIEFFER, Tara, L.ZHOU, YiZHANG, Eileen, Z.SULLIVAN, James, C.
    • KWONG, Ann, D.FRANTZ, James, DanielBARTELS, Douglas, J.LIN, ChaoSHAMES, BenjaminSEEPERSAUD, SheilaLIPPKE, Judith, A.KIEFFER, Tara, L.ZHOU, YiZHANG, Eileen, Z.SULLIVAN, James, C.
    • C12Q1/68
    • C12Q1/707C12Q1/6883
    • A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO: 12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.
    • 扩增HCV感染样品中的HCV核酸的方法包括通过两阶段PCR扩增与来自样品的HCV RNA基因组互补的DNA模板片段,其中a 第一阶段PCR使用第一外部引物和第二外部引物,并且第二阶段PCR使用第一内部引物和第二内部引物。 第一外部引物的核苷酸序列包含如SEQ ID NO:2所示的核苷酸序列; 或SEQ ID NO:9的核苷酸序列,其中任选地1,2或3个核苷酸是除SEQ ID NO:9的核苷酸以外的核苷酸。第二外部引物的核苷酸序列包含SEQ ID NO:3或4所示的核苷酸序列; 或如SEQ ID NO:10或11所示的核苷酸序列,其中任选地1,2或3个核苷酸是与SEQ ID NO:10和11的那些核苷酸不同的核苷酸。第一内部引物的核苷酸序列包含核苷酸序列 如SEQ ID NO:5所示; 或SEQ ID NO:12,其中任选地1,2或3个核苷酸是不同于SEQ ID NO:12的核苷酸。第二内部引物的核苷酸序列包含如SEQ ID NO:6或7所示的核苷酸序列 ; 或如SEQ ID NO:13或14所示的核苷酸序列,其中任选地1,2或3个核苷酸是不同于SEQ ID NO:13和14的那些核苷酸。
    • 5. 发明申请
    • FLOW-THROUGH CONCRETE EDGE FORMING SYSTEM AND METHOD
    • 流动通过混合边缘成形系统和方法
    • WO2007145891A2
    • 2007-12-21
    • PCT/US2007/013147
    • 2007-06-04
    • SULLIVAN, James, C.
    • SULLIVAN, James, C.
    • B29C33/00
    • E04G15/061E04G13/06
    • A flow-through concrete edge forming system (10) utilizes a body member (12) that has perforations (20) thereon. The body member (12) is placed at an elevation transition area of a monolithic slab (S) as an edge forming form. Once the slab (S) is poured, a parge coating (P) is placed on the outer surface of the body member (12) such that the parge coating (P) either binds to the outer surface or penetrates the body member (12) through a series of perforations on the body member (12) in order for the parge coating (P) to bind with the concrete of the slab (S) which has yet to set thereby producing a clean and solid finish of the outer surface of the slab (S) at the transition area. The body member ( 12) may have either a rectangular profile (1 12), a keyhole profile (214) or may have the perforations (20) on a series of inwardly directed deformations (18).
    • 流通式混凝土边缘形成系统(10)利用其上具有穿孔(20)的主体构件(12)。 主体构件(12)作为边缘形成形式放置在单片板(S)的仰角过渡区域。 一旦浇注了板坯(S),则在本体件(12)的外表面上放置一个涂层(P),使得该涂层涂层(P)或者结合外表面或者穿透本体件(12) 通过在本体构件(12)上的一系列穿孔,以便使涂层(P)与尚未固化的板坯(S)的混凝土结合,从而产生清洁和坚固的外表面 板坯(S)在过渡区域。 主体构件(12)可以具有矩形轮廓(112),锁眼轮廓(214)或者可以在一系列向内指向的变形(18)上具有穿孔(20)。
    • 6. 发明申请
    • METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS
    • 用于放大丙型肝炎病毒核酸的方法
    • WO2010090857A8
    • 2012-06-28
    • PCT/US2010021589
    • 2010-01-21
    • VERTEX PHARMAKWONG ANN DFRANTZ JAMES DANIELBARTELS DOUGLAS JLIN CHAOSHAMES BENJAMINSEEPERSAUD SHEILALIPPKE JUDITH AKIEFFER TARA LZHOU YIZHANG EILEEN ZSULLIVAN JAMES C
    • KWONG ANN DFRANTZ JAMES DANIELBARTELS DOUGLAS JLIN CHAOSHAMES BENJAMINSEEPERSAUD SHEILALIPPKE JUDITH AKIEFFER TARA LZHOU YIZHANG EILEEN ZSULLIVAN JAMES C
    • C12Q1/68
    • C12Q1/707C12Q1/6883
    • A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO: 12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.
    • 在HCV感染样品中扩增HCV核酸的方法包括通过两阶段PCR从样品中扩增与HCV RNA基因组互补的DNA模板的片段,其中第一阶段PCR使用第一外部引物 和第二外引物,第二阶段PCR采用第一内引物和第二内引物。 第一外引物的核苷酸序列包含SEQ ID NO:2所示的核苷酸序列; 或SEQ ID NO:9,其中任选地1,2或3个核苷酸是比SEQ ID NO:9的核苷酸更多的核苷酸。第二外部引物的核苷酸序列包含SEQ ID NO:3或4所示的核苷酸序列; 或如SEQ ID NO:10或11所示的核苷酸序列,其中任选1,2或3个核苷酸是与SEQ ID NO:10和11相同的其它核苷酸。第一内引物的核苷酸序列包含核苷酸序列 如SEQ ID NO:5所示; 或SEQ ID NO:12,其中任选地1,2或3个核苷酸是与SEQ ID NO:12相同的其它核苷酸。第二内引物的核苷酸序列包含SEQ ID NO:6或7所示的核苷酸序列 ; 或如SEQ ID NO:13或14所示的核苷酸序列,其中任选地1,2或3个核苷酸是与SEQ ID NO:13和14相同的其它核苷酸。